Clinical trials: Thinning Hair
Telogen Effluvium
Clinical Evaluation of a Nutraceutical Supplement (Olistic Women) for Hair Growth and Hair Loss in Human Volunteers
Hair loss is a multifactorial and complex condition influenced by factors such as hormonal changes, vitamin and mineral deficiencies, genetic predisposition, oxidative stress, aging, inflammation, and psychological stress.
- Trial name
- NCT07111312
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 106 people
- Sponsor
- Olistic Research Labs S.L.
Telogen Effluvium, Androgenetic Alopecia
Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia…
- Trial name
- NCT07433933
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Androgenetic Alopecia
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp
- Trial name
- NCT06149221
- Testing
- NTAP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dr. Peter C. Friedman
Androgenetic Alopecia, Acne Vulgaris
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and…
- Trial name
- NCT05428449
- Testing
- GT20029 Gel
- Where
- 2 sites in United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
To compare the efficacy and safety profiles of Teva's Diclofenac Sodium Gel, 5% (test product) to Solaraze® (diclofenac sodium) Gel, 3% (reference product) to demonstrate the clinical equivalence and to show that the efficacy of…
- Trial name
- NCT02611804
- Testing
- Diclofenac sodium
- Where
- 30 sites in United States
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Female Pattern Hair Loss, Androgenic Alopecia
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
- Trial name
- NCT02460497
- Testing
- Treatment: Minoxidil 2% / Botanical Hair Solution for Women
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
- Trial name
- BRAVE-AA2 (NCT03899259)
- Testing
- Baricitinib
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Hair Loss
Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
The study incudes 18 to 55 y/o healthy subjects with moderate hair loss stage and Fitzpatrick skin type 5 or 6
- Trial name
- NCT06885112
- Testing
- FoLix treatment for improving the scalp hair appearance
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AAJP (NCT07617597)
- Testing
- Deuruxolitinib
- Where
- 18 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Sun Pharma Japan Limited
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia Areata
Stem Cell Educator Therapy in Alopecia Areata
Alopecia Areata (AA) is one of the most common T cell-mediated autoimmune diseases, leading to the chronic and relapsing hair loss.
- Trial name
- NCT01673789
- Testing
- Stem Cell Educator
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Throne Biotechnologies Inc.
Androgenetic Alopecia
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
The study is designed to validate efficacy and long term safety of PP405.
- Trial name
- AWAKEN (NCT07819435)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia (AGA)
Phase II Study Evaluating the Efficacy and Safety of KX-826
This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 in Chinese adult male patients with AGA.
- Trial name
- NCT05940506
- Testing
- KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Gut Dysbiosis, Telogen Effluvium
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Telogen effluvium (TE) is a common cause of diffuse, non-scarring hair shedding in women. It is often triggered by physiological stress, nutritional deficiencies, illness or hormonal changes.
- Conditions
- Gut Dysbiosis, Telogen Effluvium, Hair Loss
- Trial name
- NCT07869199
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
Androgenic Alopecia
Androgenic Alopecia TH07 Clinical Trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety.
- Trial name
- MATT (NCT07435012)
- Testing
- TH07, Minoxidil 5% Topical Solution
- Where
- Canada
- Volunteers
- 420 people
- Sponsor
- Triple Hair Inc
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Hair Loss in Females
Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss
The objective of this study is to assess the hair growth efficacy of a Food for Special Medicinal Purposes (FSMP) Pantovigar® vegan after 3 and 6 months of intake.
- Trial name
- NCT05943860
- Testing
- Pantovigar® vegan
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Merz Therapeutics GmbH